$4 calls in the money now, still have 8 days to expiration. Time to take at least half profits...still has plenty of room to go, but always protect some profits.
Over $4.15 we will see a move to $4.76, $5.20, $5.64.
Resistance at $4.58
SENS has a catalyst in the next 1 - 2 months. You can take 2022 March $4 Calls. I’m holding SENS $2C 01 /20/23 @$2.5 Calls.
Breaking out of this triangle, solid move so far this week. Anticipation of FDA approval of 180 day wearable glucose monitor as the driver and potential catalyst for more...also risky for that reason
This weekly triangle is looking interesting, just starting to study this stock. Implantable glucose monitoring company...I like the chart and the tech so far...starter position could be 11/19 $4.00 calls at $0.13/$0.15
SENS Senseonics is waiting for FDA`s approval for the 180-day version of its Eversense CGM system.
Eversense can generate as much as $200 million in sales by 2025.
HC Wainwright sees a 6usd price target for it.
And let`s not forget it`s a meme stock.
Pulled SENS back up again after a few weeks and see that it's still holding the same fib and trendline levels as it was when we first drew out the fib retracement. It's also now holding the 50DMA consistently as it steadily rises. For some context, this company develops and commercializes continuous glucose monitoring systems for diabetes patients. Senseonics...
This figure is not confirmed yet.
Must break the 4$ resistance with volume to confirm.
If confirmed:
Price target = 7.50$
Stay humble, have fun, make money!
$SENS looks like it is breaking out of this symmetrical triangle. Volume is currently dying down so waiting on a pullback to enter. FDA approval is in the air and now wouldn't be a bad time to scale in! PT is previous high of $4.58 level.
Noted in the trend band, $SENS has floated within its average for the last 3 months, with a small upward move from its initial 180 day CGM submission to the FDA. Although $SENS has report net loss, it is expected from a company within its product growth cycle. Additionally, new employees were hired to speed the R & D of its programming and engineering. New...
Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a gluscose monitoring device which includes sensor, smart transmitter, and mobile application. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.
Arca
